{
    "clinical_study": {
        "@rank": "63806", 
        "arm_group": [
            {
                "arm_group_label": "FPA008 Single Dose- 1", 
                "arm_group_type": "Experimental", 
                "description": "Single infusion"
            }, 
            {
                "arm_group_label": "FPA008 Single Dose-2", 
                "arm_group_type": "Experimental", 
                "description": "Single Infusion"
            }, 
            {
                "arm_group_label": "FPA008 Single Dose-3", 
                "arm_group_type": "Experimental", 
                "description": "Single Infusion"
            }, 
            {
                "arm_group_label": "FPA008 Single Dose-4", 
                "arm_group_type": "Experimental", 
                "description": "Single Infusion"
            }, 
            {
                "arm_group_label": "FPA008 Multiple Dose-1", 
                "arm_group_type": "Experimental", 
                "description": "Dual Infusion"
            }, 
            {
                "arm_group_label": "FPA008 Multiple Dose-2", 
                "arm_group_type": "Experimental", 
                "description": "Dual Infusion"
            }, 
            {
                "arm_group_label": "FPA008 Multiple Dose-3", 
                "arm_group_type": "Experimental", 
                "description": "Dual Infusion"
            }, 
            {
                "arm_group_label": "Rheumatoid Arthritis Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "RA Treatment Regimen 1"
            }, 
            {
                "arm_group_label": "Rheumatoid Arthritis Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "RA Treatment Regimen 2"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 1, randomized, double-blind, placebo-controlled study designed in 3 parts to\n      assess the safety, tolerability, and PK of single and multiple ascending doses of FPA008 in\n      adult healthy volunteers (Parts 1 and 2) and adult subjects with active RA (Part 3)."
        }, 
        "brief_title": "Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects", 
        "condition": [
            "Healthy", 
            "Rheumatoid Arthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Part 1 and 2:\n\n          -  Healthy adult male and female subjects between the ages of 21-55 years inclusive.\n\n          -  Subject must be willing to remain in the Clinical Research Unit (CRU) for a minimum\n             of 72 hours after each dose.\n\n        Part 3:\n\n          -  RA male and female subjects between the ages of 21-70 years inclusive\n\n          -  Evidence of active RA disease\n\n          -  Inadequate response to biologic or non-biologic DMARDs\n\n          -  Subjects will be required to be on background therapy with methotrexate.\n\n        Exclusion Criteria:\n\n        Parts 1, 2 and 3:\n\n          -  BMI <18 or >32 kg/m2\n\n          -  Clinically significant findings in physical exams and laboratory tests at screening\n             and/or baseline\n\n          -  Unwilling to abstain from alcohol for 48 hours prior to study start, during CRU\n             confinement, as applicable, and for 48 hours prior to study visits.\n\n          -  Unwilling to abstain from exercise more strenuous than walking during CRU\n             confinement, as applicable, and for 48 hours prior to study visits.\n\n        Parts 1 and 2:\n\n          -  Use of any prescription, non-prescription, or herbal medications as well as\n             supplements or vitamins within 4 weeks prior to dosing, unless approved by the\n             Investigator.\n\n          -  Smoking more than 10 cigarettes, or the equivalent, per day.\n\n        Part 3:\n\n          -  Current or previous history of inflammatory joint disease other than RA\n\n          -  Evidence of extra-articular RA disease or systemic involvement\n\n          -  Currently taking any medications other than those allowed per protocol guidelines\n\n          -  Any surgical procedure including bone or joint surgery within 12 weeks prior to\n             dosing\n\n          -  Use of intra-articular (IA), intramuscular (IM), or IV corticosteroids for RA\n\n          -  Neuropathies and neurovasculopathies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "89", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01962337", 
            "org_study_id": "FPA008-001", 
            "secondary_id": "2013-003337-15"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "FPA008 Single Dose- 1", 
                    "FPA008 Single Dose-2", 
                    "FPA008 Single Dose-3", 
                    "FPA008 Single Dose-4", 
                    "FPA008 Multiple Dose-1", 
                    "FPA008 Multiple Dose-2", 
                    "FPA008 Multiple Dose-3", 
                    "Rheumatoid Arthritis Dose 1", 
                    "Rheumatoid Arthritis Dose 2"
                ], 
                "description": "Infusion", 
                "intervention_name": "FPA008", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "FPA008 Single Dose- 1", 
                    "FPA008 Single Dose-2", 
                    "FPA008 Single Dose-3", 
                    "FPA008 Single Dose-4", 
                    "FPA008 Multiple Dose-1", 
                    "FPA008 Multiple Dose-2", 
                    "FPA008 Multiple Dose-3", 
                    "Rheumatoid Arthritis Dose 1", 
                    "Rheumatoid Arthritis Dose 2"
                ], 
                "intervention_name": "Placebo Infusion", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Groningen", 
                    "country": "Netherlands"
                }, 
                "name": "PRA Early Development Services"
            }, 
            "investigator": {
                "last_name": "Sjoerd van Marle, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "9", 
        "official_title": "A Phase 1, Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Study of FPA008 in Healthy Volunteers and Subjects With Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "dalia.moawad@fiveprime.com", 
            "last_name": "Dalia Moawad, MD", 
            "phone": "4153655659"
        }, 
        "overall_official": {
            "affiliation": "Five Prime Therapeutics", 
            "last_name": "Dalia Moawad, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Ministry of Health, Welfare and Sport", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of all grade adverse events and dose limiting toxicities (DLT) during the DLT observation period and/or study treatment periods", 
            "measure": "Safety and tolerability of FPA008 adminstered in healthy volunteers and RA subjects", 
            "safety_issue": "Yes", 
            "time_frame": "within 4-12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01962337"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Five Prime Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Five Prime Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}